|
| Clinical trail | NCT number | Study type | Type of article | Study phase | Main inclusion criteria | ICI | Sample size | Proportion of gender | Median age | MPR | CPR | Incidence of TRAE | Grade 3 or higher TRAEs | Surgical resection rate | Incidence of surgical complications | Surgical delay rate | First author | Published year | Ref |
|
| CheckMate 816 | NCT02998528 | RCT | Conference abstract | III | Resectable stage I-IIIA NSCLC | Nivolumab | 21 | NR | NR | 45% (9/20) | 15% (3/20) | NR | NR | 95.2% (20/21) | NR | 0 | Felip E | 2018 | [8] |
| NEOSTAR | NCT03158129 | Cohort study | Article | II | Resectable stage I-IIIA (single N2) NSCLC | Nivolumab ± ipilimumab | 44 | 16 (36%) women and 28 (64%) men | 66 (43–83) y | 29.4% (10/34) | 17.6% (6/34) | NR | 12.2% (5/44) | 82.9% (34/41) | 29.4% (10/34) | NR | Cascone | 2021 | [9] |
| NR | NCT02716038 | Cohort study | Article | II | Resectable stage IB-IIIA NSCLC | Atezolizumab + chemo (nab-paclitaxel and carboplatin) | 30 | 15 (50%) women and 15 (50%) men | 67 (62–74) y | 56.7% (17/30) | 33.3% (10/30) | NR | NR | 86.7% (26/30) | NR | 0% | Shu CA | 2020 | [10] |
| NR | ChiCTR-OIC-17,013,726 | Cohort study | Article | Ib | Resectable stage IA-IIIB NSCLC | Sintilimab | 40 | 8 (20%) women and 32 (80%) men | 61.5 (48−70) y | 40.5% (15/37) | 16.2% (6/37) | 52.5% (21/40) | 10% (4/40) | 92.5% (37/40) | 10% (4/40) | 5% (2/40) | Gao | 2020 | [11] |
| NR | NCT02259621 | Cohort study | Article | I | Stage I-IIIA biopsy-proven NSCLC | Nivolumab | 22 | 11 (52%) women and 10 (48%) men | 67 (55–84) y | 45% (9/20) | 10% (2/20) | 23% (5/22) | 4.5% (1/22) | 91.0% (20/22) | 50% (10/20) | 0% | Bott MJ | 2019 | [12] |
| NR | NCT02259621 | Cohort study | Article | NR | Resectable stage I-IIIA NSCLC | Nivolumab | 21 | 11 (52%) women and 10 (48%) men | 67 (55–84) y | 45% (9/20) | 15% (3/20) | 23% (5/21) | 4.7% (1/21) | 95.2% (20/21) | NR | 0% | P.M. Forde | 2018 | [13] |
| NR | NCT02994576 | Cohort study | Conference abstract | II | Stage IA (≥2 cm)-IIIA non-N2, resectable, and untreated NSCLC | Atezolizumab | 30 | 15 (50%) women and 15 (50%) men | 64 y | 13.3% (4/30) | 0% | 3.3% (1/30) | 0% | 100% (30/30) | NR | 0% | Besse | 2020 | [14] |
| NADIM | NCT03081689 | Cohort study | Article | II | Resectable stage IIIA NSCLC | Nivolumab + chemo (paclitaxel and carboplatin) | 46 | 12 (26%) women and 34 (74%) men | 63 (58–70) y | 83% (34/41) | 63% (26/41) | 93% (43/46) | 30% (14/46) | 89% (41/46) | 29% (12/41) | NR | Provencio | 2020 | [15] |
| NR | NCT02259621 | Cohort study | Article | NR | Resectable stage IB –IIIA NSCLC | nivolumab + ipilimumab | 9 | 2 (22%) women and 7 (78%) men | 61.7 (48–78) y | 33% (2/6) | 33% (2/6) | 66% (6/9) | 33% (3/9) | 66.7% (6/9) | NR | 0% | Reuss JE | 2020 | [16] |
| NR | NCT02818920 | Cohort study | Article | II | Untreated clinical stage IB-IIIA NSCLC | Pembrolizumab | 30 | 14 (47%) women and 16 (53%) men | 72 (47–81) y | 28% (7/25) | 12% (3/25) | NR | 3.3% (1/30) | 83.3% (25/30) | 48% (12/25) | 4% (1/25) | Tong, B. C. | 2021 | [17] |
| NEOMUN | NCT03197467 | Cohort study | Article | II | Resectable NSCLC stage II/IIIA | Pembrolizumab | 15 | 8 women, 7 men | 59.8 (40–83) y | 27% (4/15) | 13% (2/15) | 33% (5/15) | 13% (2/15) | 100% (15/15) | 7% (1/15) | 7% (1/15) | Eichhorn, F. | 2021 | [18] |
| NR | NR | Cohort study | Article | NR | Untreated, surgically resectable stage IIB–IIIB LUSC | Pembrolizumab + chemo (nab-paclitaxel and carboplatin) | 37 | 2 (5.4%) women and 35 (94.6%) men | 62.8 (38–76) y | 64.9% (24/37) | 45.9% (17/37) | 70.3% (26/37) | 10.8% (4/37) | 100% (37/37) | NR | 0% | Shen, D. | 2021 | [19] |
| NR | NR | Cohort study | Article | NR | Stages IIA–IIIB NSCLC | PD-1 + chemo | 23 | 1 (4.3%) woman and 22 (95.7%) men | 61.83 y | 50% (10/20) | 30% (6/20) | 26% (6/23) | 4% (1/23) | 87% (20/23) | 25% (5/20) | 0% | Duan, Ht | 2021 | [20] |
| NR | NR | Cohort study | Article | NR | Stage IIIA NSCLC | PD-1 + chemo (nab-paclitaxel and carboplatin) | 72 | 6 (8.3%) women and 66 (91.7%) men | 62.2 (42–76) y | 65.2% (47/72) | 29.1% (21/72) | NR | 6.9% (5/72) | 100% (72/72) | NR | 0 | Wang Jf | 2021 | [21] |
| NR | NCT02904954 | RCT | Article | II | Resectable stage I-IIIA NSCLC | Durvalumab ± RT (8 Gy × 3) | 60 | 29 (48%) women and 31 (52%) men | 71.5 (64–75) y | 34.6% (18/52) | 15.3% (8/52) | NR | 18.3% (11/60) | 87% (52/60) | 38.5% (20/52) | 3.8% (2/52) | Altorki NK | 2021 | [22] |
| SAKK 16/14 | NCT02572843 | Cohort study | Article | II | Locally advanced T1-3N2M0, stage IIIA (N2) NSCLC | Durvalumab + chemo (docetaxel and cisplatin) | 67 | 35 (52%) men and 32 (48%) women | 61 (41–74) y | 62% (34/55) | 18% (10/55) | NR | 88% (59/67) | 82% (55/67) | NR | NR | Rothschild | 2021 | [23] |
| LCMC3 | NCT02927301 | Cohort study | Conference abstract | II | Stages IB-selected IIIB resectable NSCLC | Atezolizumab | 101 | 54 (53.5%) women and 47 (46.5%) men | 64 y | 18% (15/82) | 4.9% (4/82) | 5.9% (6/101) | NR | 98% (90/101) | 27.8% (25/90) | NR | Kwiatkowski DJ | 2019 | [24] |
| MK3475−223 | NCT02938624 | Cohort study | Conference abstract | I | Stage I-II NSCLC | Pembrolizumab | 10 | NR | NR | 40% (4/10) | NR | NR | NR | 100% (10/10) | 0% (0/10) | 0% | Bar J | 2019 | [25] |
|
